Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab.

Abstract

The pathogenesis of mastocytosis is not well defined and thus treatment remains challenging and remains on a palliative basis. We present two cases (a 48-year-old woman and a 57-year-old man) with indolent systemic mastocytosis in whom omalizumab (anti-IgE) reduced gastrointestinal and cutaneous symptoms significantly. This observation provides additional insight into the effects of omalizumab on systemic mastocytosis.

• Authors: Sofie Lieberoth, Simon Francis Thomsen
• Journal: Case reports in medicine (Case Rep Med) Vol. 2015 Pg. 903541 ( 2015) ISSN: 1687-9627 [Print] United States
• PMID: 25694784 (Publication Type: Journal Article)